BACKGROUND: Financial incentives can motivate desirable health behaviors, including adult HIV testing. Data regarding the effectiveness of financial incentives for HIV testing in children, who require urgent testing to prevent mortality, are lacking. METHODS: In a five-arm unblinded randomized controlled trial, adults living with HIV attending 19 HIV clinics in Western Kenya, with children 0-12 years of unknown HIV status, were randomized with equal allocation to $0, $1.25, $2.50, $5 or $10. Payment was conditional on child HIV testing within 2 months. Block randomization with fixed block sizes was used; participants and study staff were unblinded at randomization. Primary analysis was intent-to-treat, with predefined primary outcomes of completing child HIV testing and time to testing. RESULTS: Of 452 caregivers, 90, 89, 93, 92 and 88 were randomized to $0, $1.25, $2.50, $5.00, and $10.00, respectively. Of those, 31 (34%), 31 (35%), 44 (47%), 51 (55%), and 54 (61%) in the $0, $1.25, $2.50, $5.00, and $10.00 arms, respectively, completed child testing. Compared with the $0 arm, and adjusted for site, caregivers in the $10.00 arm had significantly higher uptake of testing [relative risk: 1.80 (95% CI 1.15--2.80), P = 0.010]. Compared with the $0 arm, and adjusted for site, time to testing was significantly faster in the $5.00 and $10.00 arms [hazard ratio: 1.95 (95% CI 1.24--3.07) P = 0.004, 2.42 (95% CI 1.55--3.79), P < 0.001, respectively). CONCLUSION: Financial incentives are effective in improving pediatric HIV testing among caregivers living with HIV. REGISTRATION: NCT03049917.
BACKGROUND: Financial incentives can motivate desirable health behaviors, including adult HIV testing. Data regarding the effectiveness of financial incentives for HIV testing in children, who require urgent testing to prevent mortality, are lacking. METHODS: In a five-arm unblinded randomized controlled trial, adults living with HIV attending 19 HIV clinics in Western Kenya, with children 0-12 years of unknown HIV status, were randomized with equal allocation to $0, $1.25, $2.50, $5 or $10. Payment was conditional on child HIV testing within 2 months. Block randomization with fixed block sizes was used; participants and study staff were unblinded at randomization. Primary analysis was intent-to-treat, with predefined primary outcomes of completing child HIV testing and time to testing. RESULTS: Of 452 caregivers, 90, 89, 93, 92 and 88 were randomized to $0, $1.25, $2.50, $5.00, and $10.00, respectively. Of those, 31 (34%), 31 (35%), 44 (47%), 51 (55%), and 54 (61%) in the $0, $1.25, $2.50, $5.00, and $10.00 arms, respectively, completed child testing. Compared with the $0 arm, and adjusted for site, caregivers in the $10.00 arm had significantly higher uptake of testing [relative risk: 1.80 (95% CI 1.15--2.80), P = 0.010]. Compared with the $0 arm, and adjusted for site, time to testing was significantly faster in the $5.00 and $10.00 arms [hazard ratio: 1.95 (95% CI 1.24--3.07) P = 0.004, 2.42 (95% CI 1.55--3.79), P < 0.001, respectively). CONCLUSION: Financial incentives are effective in improving pediatric HIV testing among caregivers living with HIV. REGISTRATION: NCT03049917.
Authors: Irene N Njuguna; Anjuli D Wagner; Vincent O Omondi; Verlinda A Otieno; Jillian Neary; Rose Bosire; Joseph B Babigumira; Carol Levin; Elizabeth Maleche-Obimbo; Dalton C Wamalwa; Grace John-Stewart; Jennifer Slyker Journal: Pediatr Infect Dis J Date: 2018-11 Impact factor: 2.129
Authors: Willy A Were; Jonathan H Mermin; Nafuna Wamai; Anna C Awor; Stevens Bechange; Susan Moss; Peter Solberg; Robert G Downing; Alex Coutinho; Rebecca E Bunnell Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Anjuli D Wagner; Gabrielle OʼMalley; Olivia Firdawsi; Cyrus Mugo; Irene N Njuguna; Elizabeth Maleche-Obimbo; Irene W Inwani; Dalton C Wamalwa; Grace C John-Stewart; Jennifer A Slyker Journal: J Acquir Immune Defic Syndr Date: 2018-04-01 Impact factor: 3.731
Authors: Habakkuk A Yumo; Rogers A Ajeh; Marcus Beissner; Jackson N Ndenkeh; Isidore Sieleunou; Michael R Jordan; Nadia A Sam-Agudu; Christopher Kuaban Journal: PLoS One Date: 2019-05-06 Impact factor: 3.240
Authors: Katherine R Simon; Robert J Flick; Maria H Kim; Rachael A Sabelli; Tapiwa Tembo; Benjamin Ryan Phelps; Nora E Rosenberg; Saeed Ahmed Journal: J Acquir Immune Defic Syndr Date: 2018-08-15 Impact factor: 3.771
Authors: Dustin G Gibson; Benard Ochieng; E Wangeci Kagucia; Joyce Were; Kyla Hayford; Lawrence H Moulton; Orin S Levine; Frank Odhiambo; Katherine L O'Brien; Daniel R Feikin Journal: Lancet Glob Health Date: 2017-04 Impact factor: 26.763
Authors: Jillian Neary; Anjuli D Wagner; Vincent Omondi; Verlinda Otieno; Cyrus Mugo; Dalton C Wamalwa; Elizabeth Maleche-Obimbo; Grace C John-Stewart; Jennifer A Slyker; Irene N Njuguna Journal: J Acquir Immune Defic Syndr Date: 2021-07-01 Impact factor: 3.771
Authors: Alexsandra Andrawis; James Tapa; Ivo Vlaev; Daniel Read; Kelly Ann Schmidtke; Eric P F Chow; David Lee; Christopher K Fairley; Jason J Ong Journal: Curr HIV/AIDS Rep Date: 2022-08-05 Impact factor: 5.495
Authors: Junyi Zhang; Dana L Atkins; Anjuli D Wagner; Irene N Njuguna; Jillian Neary; Vincent O Omondi; Verlinda A Otieno; Winnie O Atieno; Merceline Odhiambo; Dalton C Wamalwa; Grace John-Stewart; Jennifer A Slyker; Bryan J Weiner; Kristin Beima-Sofie Journal: AIDS Behav Date: 2021-06-25